Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
ABAbbVie Inc. logo

AbbVie Inc. (ABBV)

New York Stock Exchange · Currency in USD
$285.64 ▲ +0.45 (+0.16%)
At close: Oct 23, 4:01 PM ET. Market closed.
$285.34 ▼ -0.30 (-0.11%)
After hours: Oct 23, 7:21 PM ET

Summary

Previous Close
$285.19
Open
$284.58
Day's Range
$282.30 – $286.77
52 Week Range
$190.75 – $291.40
Volume
4,597,666
Avg. Volume
5,924,109
Market Cap
$504.76B
Beta (5Y Monthly)
0.28
PE Ratio (TTM)
80.47
EPS (TTM)
$3.57
Earnings Date
Oct 30, 2026
Forward Dividend & Yield
$6.92 (2.42%)
Ex-Dividend Date
Oct 15, 2026
1y Target Est
$294.00

Profile: AbbVie Inc.

Sector
Healthcare
Industry
Drug Manufacturers - General
Full-time employees
57,000
CEO
Robert A. Michael
Website
abbvie.com

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Earnings

Next report: Fri, Oct 30, 2026
EPS estimate $3.74 · Revenue est. $17.32B
DateEst.Actual
Jul 31, 2026$3.61$3.65Beat
Apr 29, 2026$2.59$2.65Beat
Feb 4, 2026$2.65$2.71Beat
Oct 31, 2025$1.77$1.86Beat
Jul 31, 2025$2.88$2.97Beat
Apr 25, 2025$2.38$2.46Beat

Analyst view

Consensus price target
$294.00 ▲ +2.9%
Range $235.00 – $325.00
Rating: Buy
Buy 70% · Hold 27% · Sell 2%

Get free alerts on ABBV and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.